Biochemical and Molecular Pharmacology in Drug Discovery comprises fundamental biochemical and molecular aspects of drug discovery and basic understanding of modern drug discovery approaches, along with certain key topics related to molecular pharmacology of drugs and therapeutics. The book explains the phenomena of drug-target interactions, considering different biochemical systems and cellular strategies. With the advent of technologies, current advances, and research trends move toward molecular and/or target-based drug design and discovery. Through this book, readers will gain skills and knowledge with a thorough understanding of the subject of biochemical and molecular pharmacology in a comprehensive and systematic manner. Molecular pharmacology has gained significant momentum among researchers, scientists, and academicians because of its increasing interest in drug discovery research across the globe. Molecular pharmacology involves a fundamental understanding of drug actions at the molecular level with the help of several tools and techniques of biochemical and molecular biology.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
1. Structure and Functions of Biomolecules2. Pharmacokinetics and Pharmacodynamics
3. Overview of Drugs and Drug Targets
4. Nucleic Acids as Drug Targets
5. Molecular Cloning of Drug Targets
6. Pharmacogenetics and pharmacogenomics in drug discovery
7. Drug-Receptor Interactions
8. Enzymology in Drug Discovery
9. Targeting Epitranscriptomics for Novel Drug Development
10. Applications of molecular pharmacology in drug discovery
11. Fundamentals of drug design and discovery
12. Fundamental Approaches of Drug Discovery
13. Enzyme Inhibitors: Design of Kinase Inhibitors as anticancer drugs
14. Reverse Pharmacology and Drug Repositioning in Drug Discovery
15. Bioinformatics and CADD Approaches in Drug Discovery
16. Artificial Intelligence-based protein structure prediction and systems biology-guided smart drug screening
17. Recombinant DNA Technology and Gene Therapy
18. Gut-Health Pharmacology: Integrating Microbiota Insights with Natural Product Therapies
19. Neuropharmacology and Neurotherapeutics: Advancing the Understanding and Treatment of Neurological Disorders
20. Molecular Oncobiology and Cancer Chemotherapeutics
21. Molecular Inflammopharmacology and Therapeutics
22. Molecular Cardiopharmacology and Therapeutics-I
23. Molecular Cardiopharmacology and Therapeutics-II
24. Molecular Endocrine Pharmacology and Therapeutics
25. Molecular Viral Infections and Anti-viral Therapeutics
Authors
Mithun Rudrapal Department of Pharmaceutical Sciences School of Biotechnology and Pharmaceutical Sciences, Vignan's Foundation for Science, Technology & Research, Guntur, India.Mithun Rudrapal, PhD, FIC, FICS, CChem (India), is Associate Professor at the Department of Pharmaceutical Sciences, School of Biotechnology & Pharmaceutical Sciences, Vignan's Foundation for Science, Technology & Research (Deemed to be University), Guntur, India. Dr. Rudrapal has been actively engaged in teaching and research in the field of Pharmaceutical and Allied Sciences for more than 13 years. He has over a hundred publications in peer-reviewed international journals to his credit and has filed a number of Indian and International patents. In addition, Dr. Rudrapal is the author of dozen published or forthcoming books. Dr. Rudrapal works in the areas of Medicinal Chemistry, CADD, Drug Repurposing, Phytochemistry, Herbal Drugs and Dietary Polyphenols.
Chukwuebuka Egbuna Africa Centre of Excellence in Public Health and Toxicological Research, University of Port Harcourt, Nigeria.Chukwuebuka Egbuna (PhD) is a chartered chemist and academic researcher. He is a member of the Institute of Chartered Chemists of Nigeria (ICCON), the Nigerian Society of Biochemistry and Molecular Biology (NSBMB), and the Royal Society of Chemistry (RSC) (United Kingdom). Dr. Egbuna is the founder and editor of the Elsevier book series on Drug Discovery Update. The series includes books, monographs, and edited collections from all areas of drug discovery including emerging therapeutic claims for the treatment of diseases. He has published research articles in many international journals of repute and is ranked among the top 500 Nigerian scientists in SciVal/SCOPUS. He has edited more than 25 books with Elsevier, Springer, Wiley, and Taylor & Francis. His most recent book is the three volume Coronavirus Drug Discovery, published by Elsevier. Dr. Egbuna is the founder and the publishing director of IPS Intelligentsia Publishing Services.
William Chi Shing Cho Queen Elizabeth Hospital, Hong Kong, China. William C.S. Cho, PhD, RCMP, FHKIMLS, FHKSMDS, Chartered Scientist (UK), FIBMS (UK). Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China. Dr. Cho's primary research interests focus on cancer research to discover biomarkers for cancer diagnosis, treatment prediction, and prognosis. As a seasoned researcher, Dr. Cho has conducted cancer research using molecular biology, proteomics, genomics, immunology, bioinformatics, and next-generation sequencing technologies. Dr. Cho has published more than 600 peer-reviewed papers (Lancet, Lancet Oncology, Annals of Oncology, Lancet Gastroenterology & Hepatology, Advanced Science, Nature Communications, PNAS, Molecular Cancer, Journal of Thoracic Oncology, Journal of the National Cancer Institute, Journal of Extracellular Vesicles, Clinical Cancer Research, Clinical Chemistry, Theranostics, etc.) covering cancer biomarkers, proteomics, noncoding RNA, traditional Chinese medicine, and dozens of books (including An Omics Perspective on Cancer Research, MicroRNAs in Cancer Translational Research, Drug Repurposing in Cancer Therapy: Approaches and Applications, Supportive Cancer Care with Chinese Medicine, etc.). The cumulative impact factor of journals exceeds 4500, and the papers have been cited >25,000 times. Dr. Cho is listed among the top 2% of the most influential scientists in the world. In addition, Dr. Cho has served as a research grant reviewer for many international research funds, including the Hope Funds for Cancer Research (United States), Cancer Research (United Kingdom), National Medical Research Council (Singapore), etc.
